Research
Diranersen showed continued benefit in Alzheimer’s trial extension at 2 years
In an open-label extension, the twice-yearly 60-mg dose had a 1.09-point treatment difference on CDR-SB at 96 weeks.

Diranersen, an investigational tau-targeting therapy, continued to show signs of slowing Alzheimer’s disease progression through 96 weeks, according to data from the phase II CELIA trial’s open-label extension. Lawren VandeVrede of the University of California San Francisco presented the findings at the Clinical Trials on Alzheimer’s Disease conference.
For participants taking 60 mg twice a year, the treatment difference on the Clinical Dementia Rating-Sum of Boxes score was 1.09 points at 96 weeks. The analysis compared 60 participants who received diranersen during the placebo-controlled phase and stayed on that dose with 115 people who switched from placebo to diranersen in the extension. VandeVrede said the treatment effect on this measure grew from 26% at week 76 to 38% at week 96.
Safety findings through week 96 were generally consistent with those from the placebo-controlled period. The most frequent adverse events included procedural pain, post-lumbar puncture syndrome, headache and confusional state. Laura Nisenbaum of the Alzheimer’s Drug Discovery Foundation said the findings need confirmation in a larger phase III trial. The extension is evaluating long-term safety, tolerability and durability of benefit.


